Global Antibiotic RandD Partnership (GARDP) Revenue and Competitors
Employee Data
- Global Antibiotic RandD Partnership (GARDP) has 99 Employees.
- Global Antibiotic RandD Partnership (GARDP) grew their employee count by 65% last year.
Global Antibiotic RandD Partnership (GARDP)'s People
Name | Title | Email/Phone |
---|
Global Antibiotic RandD Partnership (GARDP) Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 99 | 65% | N/A | N/A |
#2 | N/A | 3774 | 12% | N/A | N/A |
#3 | N/A | 123 | 7% | N/A | N/A |
#4 | N/A | 116 | 41% | N/A | N/A |
#5 | N/A | 105 | 22% | N/A | N/A |
#6 | N/A | 99 | 65% | N/A | N/A |
#7 | N/A | 90 | 34% | N/A | N/A |
#8 | N/A | 71 | 4% | N/A | N/A |
What Is Global Antibiotic RandD Partnership (GARDP)?
GARDP is a Swiss not-for-profit organization that develops new treatments for drug-resistant infections that pose the greatest threat to health. GARDP fills critical gaps by driving late-stage antibiotic development and access for people in need all over the world. GARDP’s “5 by 25” initiative aims to deliver five new treatments by 2025, including treatments for serious bacterial infections in adults, children and newborns, as well as for sexually transmitted infections. Created in 2016 by the World Health Organization (WHO) and the Drugs for Neglected Diseases initiative (DNDi) and legally founded in 2018, GARDP now works with over 70 partners in more than 20 countries with essential funding from governments and private foundations. Together, GARDP and partners are working to preserve the power of antibiotics for now and generations to come.
keywords:N/AN/A
Total Funding
99
Number of Employees
N/A
Revenue (est)
65%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $24.5M | 100 | -2% | N/A |
#2 | N/A | 101 | 33% | N/A |
#3 | $7.5M | 106 | 7% | N/A |
#4 | $24.3M | 107 | 2% | N/A |
#5 | $27.1M | 108 | 8% | N/A |